News and Events

Jun 14, 2021

The Center for Disease Control and Prevention (CDC) and the National Institute for Occupational Safety and Health (NIOSH) have found that adding in an air-bubble cushioning liner substantially improves a helmet’s shock absorption performance at high impact forces. Helmets are used to protect against traumatic brain injury and are an extremely important safety feature in construction. When helmets experience multiple impacts, their shock absorption capabilities begin to decrease.

Jun 10, 2021

NIH IRP Senior Investigator and Inventor Heinz Feldmann, M.D., was elected to the National Academy of Medicine (NAM). Dr. Feldmann is the chief of the Laboratory of Virology at the National Institute of Allergy and Infectious Diseases (NIAID). He led the development of the technology that resulted in the first Ebola vaccine approved by the FDA and the WHO. Feldmann developed this vaccine while working with other scientists at the Public Health Agency of Canada’s National Microbiology Laboratory. The vaccine uses a weakened version of a milder virus that affects certain livestock.

Jun 7, 2021

Join Michael Salgaller, NCI Invention Development and Marketing Unit, and Steven Ferguson, OTT Special Advisor, for a presentation on Technology Development and Commercialization: Impacting Pipelines and Bottom Lines. They will be speaking at the Therapeutics Area Partnerships (TAP) Oncology Conference, a specialized biopharmaceutical partnering event. This is a great opportunity to learn more about opportunities at the National Cancer Institute and ask questions.

Jun 3, 2021

Join Steven Ferguson, Deputy Director of Licensing & Entrepreneurship, NIH Office of Technology Transfer, as he speaks at the Innovation Under Pressure series on a variety of technology transfer topics. He is sharing his perspective on technology transfer, licensing and entrepreneurship, and advice to tech transfer officers and biotech CEOs, as well as his take on what has changed in terms of the business of innovation during his 30 plus years at the NIH.

May 27, 2021

In the United States, one in four cancer deaths occur from lung cancer, however, there is a lack of lung cancer screenings and analysis available quickly and at a low cost. Scientists from the National Cancer Institute’s (NCI) Laboratory of Human Carcinogenesis have proven a unique, non-invasive screening tool and diagnostic that detects lung cancer at an early stage by utilizing liquid chromatography-mass spectrometry of urine samples.

May 26, 2021

The National Cancer Institute’s (NCI) Drug Synthesis and Chemistry Branch created a potential therapeutic for various types of cancers including colon cancer and leukemia by synthesizing a fluorinated cytidine. They showed that incorporating a fluorine atom into the chemical structure of cytidine derivatives is effective in producing changes in target potency, selectivity, and overall toxicity. When used in colon cancer mouse models, this fluorinated cytidine produced complete regression of the tumors in all the mice with a response that proved durable beyond post-implant day 150.

May 20, 2021

Register for your spot at the National Cancer Institute (NCI) and Frederick National Lab’s (FNL) 2021 Technology Showcase. This event provides potential partners the opportunity to attend presentations on federal technologies ready for commercialization and/or collaboration, watch panel sessions focused on technology commercialization, see poster sessions highlighting additional NIH technologies available for licensing and collaboration, and network with regional life science professionals from a variety of sectors.

May 7, 2021

NCI investigators have developed a solution to address the challenges that nucleic acid based therapeutics face of non-specific delivery and degradation of the nanoparticles. NCI’s solution is an inducible activation nucleic acid hybrid switch. The use of nucleic acid logic elements in these constructs circumvents off-target effects. The systems were optimized to be resistant to nuclease degradation, yet inexpensive for commercial production.

May 6, 2021

The National Institute of Standards and Technology (NIST) has published a report, written by David P. Leech and John T. Scott, titled Federal Agency Return on Investment in Foreign Patenting. This report details the U.S. federal agencies’ use of foreign patents to protect their intellectual property that was created in their laboratories. The evidence presented in this report supports the view that an agency that obtains only U.S. patents for its inventions may reduce the value of licenses to use the technologies.

Apr 30, 2021

Are you interested in licensing or co-developing SARS-CoV-2 targeting antibodies? Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-receptor binding domain (RBD) single domain antibodies (also called ‘nanobodies’) from camel single domain (VHH) phage display libraries. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the RBD that binds to the angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection.